Walgreens has signed a deal with Boehringer Ingelheim to use its community pharmacies as clinical trial sites for people living with obesity and type 2 diabetes.
The drugmaker is moving into Phase III studies for survodutide, which it is developing in partnership with Zealand Pharma. It is expected to compete with other popular GLP-1 drugs currently on the market, such as Ozempic and Wegovy from Novo Nordisk. The drug has passed trials for safety and effectiveness, and the latest trials compare its efficacy with existing treatments. After the Phase III trial is completed, the company can request FDA review.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
- Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
- Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
Already have an account? Sign In
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
